title: Comparison of clinical efficacies of autologous serum eye drops in patients with primary and secondary Sjögren syndrome.
abstract: OBJECTIVE
  Autologous serum eye drops are considered to be safe and efficient for the treatment of dry eyes associated with Sjögren syndrome (SS). The purpose of this study was to compare the clinical efficacies of autologous serum eye drops in the management of primary and secondary SS.
  
  
  METHODS
  Patients with primary (n = 20; 35 eyes) and secondary (n = 14; 27 eyes) SS dry eye were included. Serum concentrations of proinflammatory cytokines [tumor necrosis factor α, interleukin (IL)-1β, IL-6, and IL-8] were measured by a multiplex immunobead assay. The ocular symptom scores, ocular staining grades, and tear break-up time were evaluated before and after 4 weeks of 50% autologous serum eye drop application.
  
  
  RESULTS
  At enrollment, patients with secondary SS had higher serum proinflammatory cytokine levels (tumor necrosis factor α, IL-1β, IL-6, and IL-8) than patients with primary SS (P < 0.01). After 4 weeks of autologous serum eye drop treatment, patients with primary SS had significantly improved ocular symptoms (P < 0.01), ocular surface staining grades (P < 0.01), and tear break-up time (P < 0.05). However, patients with secondary SS had no improvement (P > 0.05).
  
  
  CONCLUSIONS
  Our results suggest that autologous serum eye drops might not be effective for the treatment of secondary SS because of elevated serum proinflammatory cytokine levels.
authors.affiliation: *Department of Ophthalmology, Sanggye Paik Hospital, Seoul, Korea; †Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; ‡Catholic Institute of Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea; §Department of Medical Life Science, The Catholic University of Korea, Seoul, Korea; ¶Catholic High Performance Cell Therapy Center, The Catholic University of Korea, Seoul, Korea; and ‖Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Jehyung
authors.initials: J
authors.lastname: Hwang
authors.forename: So-Hyang
authors.initials: SH
authors.lastname: Chung
authors.forename: Sohee
authors.initials: S
authors.lastname: Jeon
authors.forename: Seung-Ki
authors.initials: SK
authors.lastname: Kwok
authors.forename: Sung-Hwan
authors.initials: SH
authors.lastname: Park
authors.forename: Man-Soo
authors.initials: MS
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003430:Cross-Sectional Studies; D016207:Cytokines / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage*; D011446:Prospective Studies; D044967:Serum / Q000737:chemistry / Q000502:physiology*; D012859:Sjogren's Syndrome / Q000628:therapy*; D013666:Tears / Q000737:chemistry
chemical_list: D016207:Cytokines; D009883:Ophthalmic Solutions